东阳光药业:前次IPO“折戟”,剥离、整合后曲线上市,308亿估值是否“货真价实”?丨IPO观察

钛媒体APP
31 Dec 2024

日前,广东东阳光药业股份有限公司(简称“东阳光药业”)赴港递交上市申请,计划以介绍方式在港上市,中金公司担任独家保荐人。与常见的港股冲刺不同,东阳光药业此次以介绍形式赴港,将不涉及新股发行与资金募集。东阳光药业持有港股上市公司东阳光长江药业(01558.HK)51.41%的股权,东阳光药业已提出私有化方案,将以吸收合并方式将东阳光长江药业私有化,并将根据换股比率向全体换股股东发行H股,作为换股的...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10